Polycythemia Vera clinical trials

The registry lists 278 studies for Polycythemia Vera across more than 10 countries. 53 are recruiting or about to start. 106 of them are mainly about Polycythemia Vera (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-10.

Get an email when these change. Save the Polycythemia Vera studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 147
Recruiting: 40
Terminated: 32
Active, not recruiting: 19
Withdrawn: 14
Not yet recruiting: 12

Phase

Phase 2: 121
Phase 1: 72
Phase 3: 35
Phase 4: 3
Early Phase 1: 3

Where

United States: 178
Italy: 44
France: 38
Germany: 33
United Kingdom: 27
Canada: 24

Who runs them

M.D. Anderson Cancer Center (16) · National Cancer Institute (NCI) (13) · Novartis Pharmaceuticals (12) · Fred Hutchinson Cancer Center (11) · Incyte Corporation (6) · Memorial Sloan Kettering Cancer Center (5) · Icahn School of Medicine at Mount Sinai (5) · Ronald Hoffman (5)

What is being tested here

Drugs under test in Polycythemia Vera studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Ruxolitinib	4	5	16
Pacritinib	2	2	6
Rusfertide	2	1	5
Bomedemstat	2	2	4
Ropeginterferon alfa-2b	1	6	11
Melphalan	1	1	5
Givinostat	1	1	5
Decitabine	1	0	5
Methotrexate	1	0	3
Anti-TMPRSS6 Monoclonal Antibody DISC-3405	1	0	2

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 6 open · JAK inhibitors 6 open · Antimetabolites 2 open · Alkylating agents 1 open · HDAC inhibitors 1 open

Coming up

11phase 3 studies under way

23studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Jul 2027AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms · Phase 3 · University Hospital, Brest
Nov 2026An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms · University of California, Irvine
Nov 2026Efficacy and Safety of Peginterferon in ET and PV. · Zhenya Hong
Dec 2026Long-term Study Evaluating the Effect of Givinostat in Patients With Chronic Myeloproliferative Neoplasms · Italfarmaco
Dec 2026A Clinical Study of Gecacitinib Combined With Pegylated Interferon in Patients With PV · Duan Minghui
Dec 2026A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm · AbbVie
Dec 2026A ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes · FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
Dec 2026Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms · University of Southern California
Dec 2026A Study of GLB-001 in Patients With Myeloid Malignancies · Hangzhou GluBio Pharmaceutical Co., Ltd.
Jan 2027A Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis · Memorial Sloan Kettering Cancer Center

Who these studies take

Of the 40 Polycythemia Vera studies recruiting now, 36 (90%) set no upper age limit and 1 (3%) stop at 75 or younger. 3 (8%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.

Recruiting studies that take each age, of 40
Age	Women	Men
10	2 (5%)	2 (5%)
18	38 (95%)	38 (95%)
30	39 (98%)	39 (98%)
40	39 (98%)	39 (98%)
50	39 (98%)	39 (98%)
65	40 (100%)	40 (100%)
75	40 (100%)	40 (100%)
85	39 (98%)	39 (98%)

Across all 278 studies, recruiting or not: 17% stop at 75 or younger and 8% at 65; 21% take children; 0% are for women only and 0% for men only; 2% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Polycythemia Vera studies take

Of 44 phase 2 interventional studies under Polycythemia Vera, half reached primary completion within 81 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 2	81 mo40–135 · 44 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 13, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 278. Browse all 278 → or search them.